Richard Champlin
Overview
Explore the profile of Richard Champlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
6398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smallbone P, Shigle T, Paslovsky O, Hosing C, Alousi A, Bashir Q, et al.
Haematologica
. 2025 Feb;
PMID: 40013380
Disease relapse remains the primary challenge for patients undergoing allogeneic transplantation (HSCT) for myelodysplastic syndrome (MDS). Maintenance therapies with hypomethylating agents are under investigation for use in mitigating relapse in...
2.
Rafaeli N, Costa D, Ledesma C, Jain N, Tewari P, Khouri I, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39955258
No abstract available.
3.
Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia T, Borthakur G, et al.
Am J Hematol
. 2025 Feb;
PMID: 39921561
Ontogeny of acute myeloid leukemia (AML) provides prognostic information, however closer interrogation with respect to AML characteristics, genomics, and various treatments are warranted. We defined untreated clinical secondary (CS) AML...
4.
Nieto Y, Ramdial J, Valdez B, Thall P, Bassett R, Barnett M, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39804167
Purpose: More active high-dose chemotherapy (HDC) regimens are needed for autologous stem-cell transplantation (ASCT) for refractory lymphomas. Seeking HDC enhancement with a poly(ADP-ribose) polymerase (PARP) inhibitor, we observed marked synergy...
5.
Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short N, et al.
Haematologica
. 2024 Dec;
PMID: 39665206
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospective...
6.
Marcoux C, Pasyar S, Milton D, Khan H, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Nov;
206(2):763-765.
PMID: 39610225
No abstract available.
7.
Yeh J, Pasvolsky O, Saliba R, Figgins B, Wang C, Fang Z, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Aug;
24(11):e819-e826.
PMID: 39183099
Background: FLT3-ITD AML is associated with an increased risk of relapse, leading many patients to receive an allogeneic hematopoietic stem cell transplantation (alloHCT) after induction. Unfortunately, relapse rate after alloHCT...
8.
Saengboon S, Ciurea S, Popat U, Ramdial J, Bashir Q, Alousi A, et al.
Blood Adv
. 2024 Apr;
8(12):3237-3245.
PMID: 38607399
The introduction of posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis lead to significant improvements in haploidentical stem cell transplantation (haplo-SCT) outcomes over the past decade. We retrospectively assessed long-term outcomes...
9.
Febres-Aldana A, Khawaja F, Morado-Aramburo O, Shigle T, Rondon G, Sassine J, et al.
Clin Microbiol Infect
. 2024 Mar;
30(6):803-809.
PMID: 38460821
Objectives: Allogeneic haematopoietic cell transplant (allo-HCT) recipients who are cytomegalovirus (CMV)-seronegative have better post-transplant outcomes than CMV-seropositive recipients. Letermovir (LTV) is approved for CMV primary prophylaxis in adults who are...
10.
Alzahrani K, Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Mar;
204(5):1944-1952.
PMID: 38448009
The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the...